Abstract：Objective: To study influence of effect and symptom scores of montelukast and terbutaline in the treatment of children patients with bronchial asthma. Methods: 124 children with bronchial asthma who were treated in our hospital from June 2014 to December 2016 were enrolled in this study. The children were divided into observation group and control group with 62 cases in each group, the two groups were given routine anti infection, oxygen inhalation, and relieving asthma and bronchiectasis and other related drugs. The control group was treated with terbutaline inhalation, while the observation group based on the control group of the drug, plus taking montelukast. After 2 months of treatment, the curative effect of the treatment group was compared with that of the two groups (FEV1, PEF and FEV1/FVC), symptom scores and adverse reactions. Results: The clinical control rate of the observation group was 40.32%, the total effective rate was 98.39%, which were significantly higher than the control group of 17.74% and 88.71%, the difference was statistically significant (P < 0.05). After treatment, the levels of FEV1, PEF and FEV1/FVC in the two groups were significantly higher than those before treatment, the observation group was significantly higher than the control group, the difference was statistically significant (P < 0.05). After treatment, the two groups were significantly lower than those in the control group in the day and night symptom scores, and the observation group was significantly lower than the control group, the difference was statistically significant (P < 0.05). The total incidence of adverse reactions in the observation group was 6.45%, compared with the control group of 11.29%, the difference was not statistically significant (P > 0.05). Conclusion: Montelukast and terbutaline in the treatment of children with bronchial asthma has a good effect, but also can effectively improve the symptom score.
杨硕, 洪源, 党媛媛. 孟鲁司特及特布他林联用对支气管哮喘患儿的疗效及症状评分的影响[J]. 河北医学, 2018, 24(2): 317-321.
YANG Shuo, HONG Yuan, DANG Yuanyuan. Influence of Effect and Symptom Scores of Montelukast and Terbutaline in the treatment of Children Patients with Bronchial Asthma. HeBei Med, 2018, 24(2): 317-321.
[1] 张天宇.孟鲁司特钠防治咳嗽变异性哮喘的疗效观察[J].中国卫生标准管理,2015,6(13):153~154. [2] 汤运红.支气管哮喘应用盐酸氨溴索辅以特布他林雾化加温吸入的临床研究[J].中国处方药,2016,14(5):48~49. [3] 王爱珍,楼黎明.孟鲁司特、特布他林联合治疗儿童支气管哮喘的临床研究[J].中国现代医生,2016,54(4):46~49. [4] Whalley D, Petigara T, Rasouliyan L,et al.Early patient experiences with montelukast orally disintegrating tablets in Japan: a cross-sectional survey of treatment satisfaction in patients with asthma and/or allergic rhinitis[J].Curr Med Res Opin,2017,33(2):215~223. [5] 李本慧,许艳强,崔海西,等.布地奈德联合特布他林雾化吸入治疗哮喘患儿的临床疗效[J].中国药物经济学,2016,11(5):50~52. [6] Wei Y, Li DS, Liu JJ,et al.Therapeutic effect and safety of montelukast sodium combined with budesonide in children with cough variant asthma: a Meta analysis[J].Zhongguo Dang Dai Er Ke Za Zhi,2016,18(11):1100~1105. [7] 李海英,殷果.用孟鲁司特钠对成年哮喘患者进行治疗的效果评析[J].当代医药论丛,2016,14(10):97~98. [8] 刘亚欣.特布他林结合布地奈德雾化吸入用于小儿哮喘治疗的疗效探究[J].临床研究,2016,24(7):77~78. [9] 李红霞.布地奈德与特布他林联合雾化吸入治疗儿童支气管哮喘急性发作的疗效观察[J].中国医院用药评价与分析,2016,16(4):451~453. [10] 马越.布地奈德、特布他林溶液联合吸入对哮喘呼气流速改善的观察[J].中国实用医药,2016,11(29):128~130. [11] 李草旎.孟鲁斯特联合布地奈德和特布他林治疗哮喘急性发作的疗效观察[J].现代药物与临床,2015,30(10):1225~1228. [12] Aagaard L, Hansen EH.Paediatric adverse drug reactions following use of asthma medications in Europe from 2007 to 2011[J].Int Clin Pharm,2014,36(6):1222~1229. [13] 张凤宇,刘晓荣,吴秀军,等.雾化吸入布地奈德及特布他林联合孟鲁斯特治疗哮喘急性发作临床观察[J].中国综合临床,2012,28(2):133~135. [14] Gong L, Xu L, Diao M,et al.Clinical effect of treating secondary asthma attacks of children Mycoplasma pneumoniae with combined therapy of montelukast and azithromycin[J].Eur Rev Med Pharmacol Sci,2016,20(24):5256~5260. [15] Tenero L, Piazza M, Sandri M,et al.Effect of montelukast on markers of airway remodeling in children with asthma[J].Allergy Asthma Proc,2016,37(5):77~83.
2018, Vol. 24 
冀公网安备13080202000677号